Lidoderm Antitrust

A drug maker that dropped its patent suit against makers of the pain patch Lidoderm and agreed to delay its generic version could have won its lawsuit, an “alternate injury in a but-for world” that precludes resolving a sprawling antitrust <a href="https://www.courthousenews.com/class-certified-in-lidoderm-antitrust-case/">class action</a> in the drug makers’ favor, a federal judge has <strong><a href="http://www.courthousenews.com/wp-content/uploads/2017/11/Lidoderm-SJ-ORDER.pdf">ruled.</a></strong>

SAN FRANCISCO – A drug maker that dropped its patent suit against makers of the pain patch Lidoderm and agreed to delay its generic version could have won its lawsuit, an “alternate injury in a but-for world” that precludes resolving a sprawling antitrust class action in the drug makers’ favor, a federal judge has ruled.

Categories / Business, Courts, Health

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.